/

BEAM

Beam Therapeutics Inc.Open

24.35−0.78 −3.10%USD

NasdaqGS · as of Oct 13, 11:21 ET · 15m delay

Open

24.84

Prev close

25.13

Day range

24.2924.93

52-week range

20.2338.26

Volume

373.55K0.20×

Mkt cap

2.52B

P/E ttm

—

Fwd P/E

-5.14

EPS ttm

-0.6800

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−36.36%

Price Chart

Yahoo Finance · delayed

BEAMOct 13, 2026O 24.84H 24.93L 24.29C 24.35−0.78 (−3.10%)Vol 373.55K

SMA 5026.48
SMA 20028.41

1Y change −7.48% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BEAM Beam Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.49%
1 month: +1.50%
3 months: −21.17%
6 months: −19.64%
Year to date: −12.16%
1 year: −4.10%

Valuation & ownership

Market cap: 2.52B
Enterprise value: 1.61B
P/E (ttm): —
Forward P/E: -5.14
PEG ratio: —
Price / book: 2.28
Price / sales (ttm): 16.12
EV / EBITDA: -4.51
EPS (ttm): -0.6800
EPS (forward): -4.74
Beta (5y monthly): 2.20
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 103.29M
Float: 88.33M
Short % of float: 41.24%
Short ratio (days): 14.33
Held by insiders: 1.20%
Held by institutions: 107.91%
Avg volume (3m): 1.88M
50-day average: 26.51
200-day average: 28.43
52-week change: −4.10%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 43.5
vs 50-day SMA: −8.03%
vs 200-day SMA: −14.29%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.59%
Realised vol (20d, ann.): 45.9%
From 52-week high: −36.36%
From 52-week low: +20.37%

ANR

Analyst Consensus

13 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

52.15

+114.18% implied

Low 26.00Median 45.00High 80.00

Recommendation trend

Now13 / 2 / 0
1m ago / 2 /

DES

About Beam Therapeutics Inc.

Yahoo Finance profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 540
Headquarters: Cambridge, MA, United States
Website: beamtx.com
Officers: Mr. John M. Evans M.B.A. CEO & Director

SEAS

Seasonality · BEAM

2020–2026 · monthly returns

Strongest month Nov +16.56%Weakest month Mar −20.52%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.4	3.0	-16.3	27.3	8.6	4.2	-25.6	15.3	-16.9	-0.4			−12.2%
2025	4.5	1.6	-25.9	2.0	-20.6	7.5	15.9	-17.0	48.3	3.0	1.3	9.4	+11.8%
2024	-10.4	61.8	-16.3	-35.8	12.3	-1.6	35.0	-15.7	-8.2	-10.6	24.9	-9.4	−8.9%
2023	11.1	-7.4	-23.9	0.3	3.9	0.1	-3.3	-24.9	3.8	-12.1	32.8	-3.1	−30.4%
2022	-13.2	13.2	-26.9	-34.5	-6.3	10.0	62.7	-13.3	-12.7	-7.5	4.8	-15.3	−50.9%
2021	18.1	-7.6	-10.2	2.4	-4.6	64.5	-28.5	20.6	-21.6	2.0	-10.8	0.7	−2.4%
2020			-20.0	-11.4	60.2	9.6	-30.9	29.8	-2.0	38.8	46.3	63.3	+263.0%

INSD

Insider Activity · BEAM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

85.5K shares

Sells, 6 months

351.9K shares

Net shares

−266.4K

Net change in insider shares

−18.10%

Date	Insider	Transaction	Shares	Value
Jul 26, 2026	Simon AmyOfficer	Sale at price 25.74 per share.	16.7K	$429.04K
Jun 29, 2026	Simon AmyOfficer	Sale at price 34.73 per share.	373	$12.95K
Jun 29, 2026	Evans John M.Chief Executive Officer	Sale at price 34.26 - 35.91 per share.	50K	$1.75M
Jun 29, 2026	Evans John M.Chief Executive Officer	Conversion of Exercise of derivative security at price 0.67 - 1.03 per share.	50K	$44.78K
Jun 25, 2026	Fmr, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Sale at price 35.12 - 35.26 per share.	284.9K	$10.04M
Jun 16, 2026	Ciaramella GiuseppePresident	Conversion of Exercise of derivative security at price 0.67 - 1.03 per share.	35.5K	$34.23K
Mar 31, 2026	Evans John M.Chief Executive Officer	Sale at price 24.58 per share.	30.1K	$739.32K
Mar 31, 2026	Bellon ChristineOfficer	Sale at price 24.58 per share.	6K	$146.40K
Mar 31, 2026	Simon AmyOfficer	Sale at price 24.58 per share.	6.7K	$164.69K
Mar 31, 2026	Cavanagh Bethany JOfficer and Treasurer	Sale at price 24.58 per share.	3.2K	$79.69K
Mar 31, 2026	Ciaramella GiuseppePresident	Sale at price 24.58 per share.	11.8K	$290.29K
Mar 30, 2026	Evans John M.Chief Executive Officer	Conversion of Exercise of derivative security at price 0.67 per share.	50K	$33.50K
Mar 30, 2026	Emany Sravan KumarChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	31.8K	—
Mar 30, 2026	Bellon ChristineOfficer	Stock Award(Grant) at price 0.00 per share.	20K	—
Mar 30, 2026	Simon AmyOfficer	Stock Award(Grant) at price 0.00 per share.	31.8K	—
Mar 30, 2026	Cavanagh Bethany JOfficer and Treasurer	Stock Award(Grant) at price 0.00 per share.	20K	—
Mar 30, 2026	Ciaramella GiuseppePresident	Stock Award(Grant) at price 0.00 per share.	40K	—
Mar 30, 2026	Evans John M.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	90K	—
Mar 30, 2026	Evans John M.Chief Executive Officer	Sale at price 22.37 - 22.76 per share.	50K	$1.13M
Feb 23, 2026	Ciaramella GiuseppePresident	Sale at price 32.00 per share.	35K	$1.12M

13F

Investors Holding BEAM

latest 13F filings of 29 followed managers

Investors holding BEAM
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$351.3M	2.28%	10.23M	−16%	Q2 2026
Renaissance Technologies	$15.3M	0.02%	445.00K	−13%	Q2 2026
Duquesne Family Office · Stanley Druckenmiller	$5.3M	0.10%	153.60K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

BEAM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BEAM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Beam Therapeutics Inc.

Seasonality · BEAM

Insider Activity · BEAM

Congress Trades · BEAM

Investors Holding BEAM

Investors Holding BEAM

Congress Trades · BEAM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Beam Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News

Insider Activity · BEAM

Seasonality · BEAM